Shares of animal health company Elanco (NYSE:ELAN)
jumped 8.2% in the morning session after the company reported fourth-quarter results that surpassed Wall Street's expectations, with investors focusing on strong current performance over a mixed outlook for 2026. For the quarter,
Animal health company Elanco (NYSE:ELAN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 12.2% year on year to $1.14 billion. Guidance for next quarter’s revenue was better than expected at $1.29 billion at the midpoint, 1% above analysts’ estimates. Its non-GAAP profit of $0.13 per share was 15.6% above analysts’ consensus estimates.
Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026, the company finds itself at a pivotal crossroads. While it continues to dominate the multi-billion dollar markets for companion animal medicines [...]
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
In a decisive move to protect the nation’s multi-billion dollar livestock industry, U.S. Secretary of Agriculture Brooke Rollins announced today, February 5, 2026, the launch of a $100 million "New World Screwworm Grand Challenge." The federal initiative is designed to spur rapid innovation in the detection, containment, and
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
The past six months have been a windfall for Elanco’s shareholders. The company’s stock price has jumped 64.6%, setting a new 52-week high of $23.81 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
As the curtain closes on 2025, the healthcare sector has emerged as a landscape of stark contrasts. While traditional pharmaceutical giants have grappled with the implementation of the Medicare Part D out-of-pocket caps and shifting regulatory winds, two specific "growth pockets"—animal health and specialty/complex generics—have captured investor
In a significant strategic shift that marks the end of a multi-year regulatory odyssey, ImmuCell Corporation (Nasdaq: ICCC) announced late yesterday, December 23, 2025, that it has received another Technical Section Incomplete Letter from the U.S. Food and Drug Administration (FDA) regarding its subclinical mastitis treatment, Re-Tain. The letter,
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of animal health company Elanco (NYSE:ELAN)
jumped 2.4% in the afternoon session after several top executives, including the CEO and CFO, disclosed significant purchases of company stock, signaling strong internal confidence.
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.
NICE sits at the center of two critical enterprise markets: customer experience and financial crime prevention. This piece breaks down what is changing inside the business and why its next phase of cloud and AI adoption matters for investors.
